Curated News
By: NewsRamp Editorial Staff
September 21, 2026
Helus Pharma Presents HLP003 Data at Psych Congress 2026
TLDR
- Helus Pharma's HLP003 holds FDA Breakthrough Therapy Designation and leads in Phase 3 for major depressive disorder.
- HLP003 is an oral deuterated psilocin analog that activates serotonin pathways to promote neuroplasticity in depression treatment.
- Helus Pharma aims to help minds heal by developing novel treatments for depression and anxiety to improve lives.
- Helus Pharma presented four posters on HLP003 at Psych Congress 2026, including 12-month efficacy and safety data.
Impact - Why it Matters
The presentation of promising 12-month efficacy and safety data for HLP003 at Psych Congress 2026 underscores the potential of novel serotonergic agonists as a new class of antidepressants. With major depressive disorder affecting millions worldwide and many patients not achieving adequate relief from existing therapies, HLP003's Breakthrough Therapy Designation and advancement into Phase 3 trials signal a possible paradigm shift. If approved, HLP003 could offer a much-needed adjunctive treatment option that provides durable improvements, addressing a significant unmet need in mental health care. This news matters because it brings hope for more effective, fast-acting, and long-lasting depression treatments, potentially transforming the lives of those who struggle with this debilitating condition.
Summary
Helus Pharma(TM) (NASDAQ: HELP) (Cboe CA: HELP), the commercial operating name of Cybin Inc., made a significant showing at Psych Congress 2026 in New Orleans by presenting four posters on its investigational oral deuterated psilocin analog, HLP003. The company is developing HLP003 as an adjunctive treatment for major depressive disorder (MDD). Three of the presentations build on Helus Pharma's completed Phase 1/2a randomized, double-blind study, featuring 12-month efficacy results, analyses of anhedonia and the psychedelic experience, and expanded safety data. Additionally, the company provided a trial-in-progress overview of PARADIGM, its ongoing Phase 3 clinical program evaluating HLP003's efficacy and safety as an adjunctive MDD treatment. For full details, visit the full press release.
Helus Pharma, founded in 2019, is a clinical-stage pharmaceutical company committed to helping minds heal by developing proprietary novel serotonergic agonists (NSAs)—synthetic molecules designed to activate serotonin pathways believed to promote neuroplasticity. These NSAs aim to address the large unmet need for people suffering from depression, anxiety, and other mental health conditions. With class-leading data, Helus Pharma seeks to improve the treatment landscape through NSAs that provide durable improvements in mental health. The company is currently developing HLP003 in Phase 3 for adjunctive MDD treatment, which has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration, and HLP004 in Phase 2 for generalized anxiety disorder. Helus Pharma operates in Canada, the United States, the United Kingdom, and Ireland. For more information, visit www.helus.com or follow the team on social media. The latest updates relating to HELP are available in the company's newsroom at https://ibn.fm/HELP.
The announcement was disseminated through PsychedelicNewsWire (PNW), a specialized communications platform focused on psychedelics. PNW is part of the Dynamic Brand Portfolio @ IBN, which offers access to a vast network of wire solutions via InvestorWire, article and editorial syndication to 5,000+ outlets, enhanced press release enhancement, social media distribution, and tailored corporate communications solutions. This article has been disseminated on behalf of Helus Pharma and may include paid advertising.
Source Statement
This curated news summary relied on content distributed by InvestorBrandNetwork (IBN). Read the original source here, Helus Pharma Presents HLP003 Data at Psych Congress 2026
